

SAMENVATTING Hovon 902

TITEL

A national study for blood based response monitoring of newly diagnosed aggressive B-cell lymphoma (DLBCL and HGBCL) patients

INDICATIE


Patients with newly diagnosed DLBCL and HGBCL ≥ 18 yr.

SCHEMA

HOVON 902: All newly diagnosed DLBCL/HGBCL patients

HOVON 902:

1. Permission for drawing blood samples (11x in 2 year)
2. Permission for genomic analysis on lymphoma samples
3. Permission to use clinical outcome data (via HOVON-IKNL)



*if the patient is included in the HOVON 151 or HOVON 152, the collection of blood sampling for HOVON 902 will stop (as taking blood samples is already foreseen in these protocols).

INCLUSIE CRITERIA

- Patients diagnosed with newly diagnosed DLBCL (including HGBCL-NOS and HGBCL-DH) according to WHO classification 2016
- Ann Arbor stage II-IV
- Patients intended to be treated with 6 cycles R-CHOP (or DA-EPOCH-R) as first-line treatment (successive inclusion in HOVON 151 or HOVON 152 is possible)
- Age ≥ 18 years

EXCLUSIE CRITERIA

- Patients with limited stage I,II disease planned to receive 3 cycles of R-CHOP + radiotherapy, or 4 x R-CHOP+ 2R